Lam, J. S. Leppert, J. T. Figlin, R. A. Belldegrun, A. S.   Surveillance following radical or partial nephrectomy for renal cell carcinoma Curr Urol Rep, 2005; 6(1): 7-18.

Lam, JS Belldegrun, AS Figlin, RA   Advances in immune-based therapies of renal cell carcinoma Expert review of anticancer therapy. , 2004; 4(6): 1081-96.

Atkins, M. B. Avigan, D. E. Bukowski, R. M. Childs, R. W. Dutcher, J. P. Eisen, T. G. Figlin, R. A. Finke, J. H. Flanigan, R. C. George, D. J. Goldberg, S. N. Gordon, M. S. Iliopoulos, O. Kaelin, W. G., Jr. Linehan, W. M. Lipton, A. Motzer, R. J. Novick, A. C. Stadler, W. M. Teh, B. T. Yang, J. C. King, L.   Innovations and challenges in renal cancer: consensus statement from the first international conference Clin Cancer Res, 2004; 10(18 Pt 2): 6277S-81S.

Lam, JS Belldegrun, AS Figlin, RA   Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy Clinical cancer research : an official journal of the American Association for Cancer Research. , 2004; 10(18 Pt 2): 6304S-9S.

Figlin, RA Alvin, H Meinhardt, CL   Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma Der Urologe. Ausg. A. , 2004; 43 Suppl 3: 144-5.

Patard, JJ Kim, HL Lam, JS Dorey, FJ Pantuck, AJ Zisman, A Ficarra, V Han, KR Cindolo, L De La Taille, A Tostain, J Artibani, W Dinney, CP Wood, CG Swanson, DA Abbou, CC Lobel, B Mulders, PF Chopin, DK Figlin, RA Belldegrun, AS   Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2004; 22(16): 3316-22.

Kim, HL Seligson, D Liu, X Janzen, N Bui, MH Yu, H Shi, T Figlin, RA Horvath, S Belldegrun, AS   Using protein expressions to predict survival in clear cell renal carcinoma Clinical cancer research : an official journal of the American Association for Cancer Research. , 2004; 10(16): 5464-71.

Han, KR Janzen, NK McWhorter, VC Kim, HL Pantuck, AJ Zisman, A Figlin, RA Dorey, FJ Said, JW Belldegrun, AS   Cystic renal cell carcinoma: biology and clinical behavior Urologic oncology. , 2004; 22(5): 410-4.

Suh, R. D. Goldin, J. G. Wallace, A. B. Sheehan, R. E. Heinze, S. B. Gitlitz, B. J. Figlin, R. A.   Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment Radiology, 2004; 231(2): 359-64.

Pantuck, AJ van Ophoven, A Gitlitz, BJ Tso, CL Acres, B Squiban, P Ross, ME Belldegrun, AS Figlin, RA   Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer Journal of immunotherapy (Hagerstown, Md. : 1997) , 2004; 27(3): 240-53.

Patard, J. J. Dorey, F. J. Cindolo, L. Ficarra, V. De La Taille A Tostain, J. Artibani, W. Abbou, C. C. Lobel, B. Chopin, D. K. Figlin, R. A. Belldegrun, A. S. Pantuck, A. J.   Symptoms As Well As Tumor Size Provide Prognostic Information On Patients With Localized Renal Tumors J Urol, 2004; 172(6, Part 1 of 2): 2167-2171.

Bui, MH Visapaa, H Seligson, D Kim, H Han, KR Huang, Y Horvath, S Stanbridge, EJ Palotie, A Figlin, RA Belldegrun, AS   Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma The Journal of urology. , 2004; 171(6 Pt 1): 2461-6.

Patard, JJ Shvarts, O Lam, JS Pantuck, AJ Kim, HL Ficarra, V Cindolo, L Han, KR De La Taille, A Tostain, J Artibani, W Abbou, CC Lobel, B Chopin, DK Figlin, RA Mulders, PF Belldegrun, AS   Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience The Journal of urology. , 2004; 171(6 Pt 1): 2181-5, quiz 2435.

Kim, HL Han, KR Zisman, A Figlin, RA Belldegrun, AS   Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma The Journal of urology. , 2004; 171(5): 1810-3.

Han, KR Kim, HL Pantuck, AJ Dorey, FJ Figlin, RA Belldegrun, AS   Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma Urology. , 2004; 63(5): 841-6; discussion 846-7.

Seligson, DB Pantuck, AJ Liu, X Huang, Y Horvath, S Bui, MH Han, KR Correa, AJ Eeva, M Tze, S Belldegrun, AS Figlin, RA   Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma Clinical cancer research : an official journal of the American Association for Cancer Research. , 2004; 10(8): 2659-69.

Foon, KA Yang, XD Weiner, LM Belldegrun, AS Figlin, RA Crawford, J Rowinsky, EK Dutcher, JP Vogelzang, NJ Gollub, J Thompson, JA Schwartz, G Bukowski, RM Roskos, LK Schwab, GM   Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody International journal of radiation oncology, biology, physics. , 2004; 58(3): 984-90.

Mukouyama, H. Janzen, N. K. Hernandez, J. M. Lam, J. S. Caliliw, R. Wang, A. Y. Figlin, R. A. Belldegrun, A. S. Zeng, G.   Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9 Clin Cancer Res, 2004; 10(4): 1421-9.

Kim, HL Zisman, A Han, KR Figlin, RA Belldegrun, AS   Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? The Journal of urology. , 2004; 171(2 Pt 1): 588-91.

Leibovich, BC Han, KR Bui, MH Pantuck, AJ Dorey, FJ Figlin, RA Belldegrun, A   Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials Cancer. , 2003; 98(12): 2566-75.

Han, KR Bleumer, I Pantuck, AJ Kim, HL Dorey, FJ Janzen, NK Zisman, A Dinney, CP Wood, CG Swanson, DA Said, JW Figlin, RA Mulders, PF Belldegrun, AS   Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population The Journal of urology. , 2003; 170(6 Pt 1): 2221-4.

Gitlitz, BJ Baker, C Chapman, Y Allen, HJ Bosserman, LD Patel, R Sanchez, JD Shapiro, RM Figlin, RA   A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma Cancer. , 2003; 98(9): 1863-9.

Kiertscher, S. M. Gitlitz, B. J. Figlin, R. A. Roth, M. D.   Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients Int J Cancer, 2003; 107(2): 256-61.

Kim, HL Belldegrun, AS Freitas, DG Bui, MH Han, KR Dorey, FJ Figlin, RA   Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis The Journal of urology. , 2003; 170(5): 1742-6.

Pantuck, AJ Zeng, G Belldegrun, AS Figlin, RA   Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway Clinical cancer research : an official journal of the American Association for Cancer Research. , 2003; 9(13): 4641-52.

Thompson, J. A. Figlin, R. A. Sifri-Steele, C. Berenson, R. J. Frohlich, M. W.   A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma Clin Cancer Res, 2003; 9(10 Pt 1): 3562-70.

Palapattu, GS Pantuck, AJ Dorey, F Said, JW Figlin, RA Belldegrun, AS   Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies The Journal of urology. , 2003; 170(3): 768-72; discussion 772.

Clark, JI Atkins, MB Urba, WJ Creech, S Figlin, RA Dutcher, JP Flaherty, L Sosman, JA Logan, TF White, R Weiss, GR Redman, BG Tretter, CP McDermott, D Smith, JW Gordon, MS Margolin, KA   Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2003; 21(16): 3133-40.

Gitlitz, BJ Belldegrun, AS Zisman, A Chao, DH Pantuck, AJ Hinkel, A Mulders, P Moldawer, N Tso, CL Figlin, RA   A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma Journal of immunotherapy (Hagerstown, Md. : 1997) , 2003; 26(5): 412-9.

Gitlitz, BJ Figlin, RA   Cell, gene and vaccine based strategies in kidney cancer Cancer treatment and research. , 2003; 116: 183-98.

Gitlitz, B. J. Figlin, R. A.   Cytokine-based therapy for metastatic renal cell cancer Urol Clin North Am, 2003; 30(3): 589-600.

Hernandez, J. M. Bui, M. H. Han, K. R. Mukouyama, H. Freitas, D. G. Nguyen, D. Caliliw, R. Shintaku, P. I. Paik, S. H. Tso, C. L. Figlin, R. A. Belldegrun, A. S.   Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene Clin Cancer Res, 2003; 9(5): 1906-16.

Gitlitz, B. J. Figlin, R. A. Kiertscher, S. M. Moldawer, N. Rosen, F. Roth, M. D.   Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer J Immunother, 2003; 26(2): 171-8.

Pantuck, AJ Zisman, A Dorey, F Chao, DH Han, KR Said, J Gitlitz, B Belldegrun, AS Figlin, RA   Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy Cancer. , 2003; 97(12): 2995-3002.

Janzen, N. K. Kim, H. L. Figlin, R. A. Belldegrun, A. S.   Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am, 2003; 30(4): 843-52.

Han, K. R. Bui, M. H. Pantuck, A. J. Freitas, D. G. Leibovich, B. C. Dorey, F. J. Zisman, A. Janzen, N. K. Mukouyama, H. Figlin, R. A. Belldegrun, A. S.   TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion J Urol, 2003; 169(3): 899-903; discussion 903-4.

Pantuck, AJ Zisman, A Dorey, F Chao, DH Han, KR Said, J Gitlitz, BJ Figlin, RA Belldegrun, AS   Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection The Journal of urology. , 2003; 169(6): 2076-83.

Zisman, A Wieder, JA Pantuck, AJ Chao, DH Dorey, F Said, JW Gitlitz, BJ deKernion, JB Figlin, RA Belldegrun, AS   Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy The Journal of urology. , 2003; 169(3): 909-16.

Bui, MH Seligson, D Han, KR Pantuck, AJ Dorey, FJ Huang, Y Horvath, S Leibovich, BC Chopra, S Liao, SY Stanbridge, E Lerman, MI Palotie, A Figlin, RA Belldegrun, AS   Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clinical cancer research : an official journal of the American Association for Cancer Research. , 2003; 9(2): 802-11.

Kim, HL Belldegrun, AS Figlin, RA   Immune gene therapy for kidney cancer: the search for a magic trigger Molecular therapy : the journal of the American Society of Gene Therapy. , 2003; 7(2): 153-4.

Han, KR Pantuck, AJ Bui, MH Shvarts, O Freitas, DG Zisman, A Leibovich, BC Dorey, FJ Gitlitz, BJ Figlin, RA Belldegrun, AS   Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma Urology. , 2003; 61(2): 314-9.